News-Medical.netHavard University grants license to Beam Therapeutics to develop new base editing technologyNews-Medical.netGenome editing technologies using the CRISPR platform in combination with enzymes like Cas9 and Cpf1 have shown great promise fo… Continue reading
News-Medical.netHavard University grants license to Beam Therapeutics to develop new base editing technologyNews-Medical.netGenome editing technologies using the CRISPR platform in combination with enzymes like Cas9 and Cpf1 have shown great promise fo… Continue reading
Synthetic Biology Market balanced to Reach Insignificant CAGR till 2024Coherent Chronicle (press release) (blog)Developed countries such as the U.S., Germany, U.K., France, and Japan have mature markets for synthetic biology mainly due to large funding… Continue reading
Precision BioSciences to Present In Vivo Gene Therapy and Ex Vivo Cancer Immunotherapy Data at the American …WV NewsDURHAM, N.C.–(BUSINESS WIRE)–May 14, 2018–Precision BioSciences, the ARCUS genome editing company with novel product development pr… Continue reading
Precision BioSciences to Present In Vivo Gene Therapy and Ex Vivo Cancer Immunotherapy Data at the American …Watertown Public OpinionDURHAM, N.C.–(BUSINESS WIRE)–May 14, 2018–Precision BioSciences, the ARCUS genome editing company with novel produ… Continue reading
NJBIZ |
Immunotherapy specialist relocating to NJ
NJBIZ Daniel O’Connor, CEO at startup life sciences company OncoSec, moved the company’s executive staff to Pennington due to the state’s Economic Development Authority’s Technology Business Tax Certificate Transfer Program. – (DAVID SCHEMELIA). |
MIT Technology Review |
Here comes a more precise version of CRISPR
MIT Technology Review CRISPR 2.0: The traditional CRISPR system cuts a whole gene—a sequence of different base letters—to make a break in DNA’s double-helix structure. Liu’s base editors directly convert a single base into another, changing the gene from the mutated to … Beam Therapeutics Spotlights CRISPR 2.0 with Precise Gene Editor, $87MXconomy A pencil, not a pair of scissors: CRISPR pioneers’ new company bets on base editing to cure diseaseSTAT Feng Zhang’s base-editing CRISPR startup officially launches with $87MFierceBiotech Endpoints News –Chemical & Engineering News –Financial Times all 10 news articles » |